



0300/\$ PATENT  
Docket No. 2026-4255

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Emerson, S.U. et al. Group Art Unit: 1815  
Serial No. : 08/840,316 Examiner: To Be Assigned  
Filed : April 11, 1997  
For : RECOMBINANT PROTEINS OF A PAKISTANI STRAIN OF HEPATITIS E AND  
THEIR USE IN DIAGNOSTIC METHODS AND VACCINES

CERTIFICATE OF MAILING (37 C.F.R. 1.8a)

ASSISTANT COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

Sir:

I hereby certify that the attached (1) Notice of Missing Parts; (2) Executed Combined Declaration and Power of Attorney; (3) Paper Copy of Sequence Listing; (4) Computer Disk Copy of Sequence Listing; (5) Statement Under 37 C.F.R. §1.821(f); (6) Declaration Transmittal Form and Check for \$130.00; (7) Preliminary Amendment; and (8) Return postcard (along with any paper(s) referred to as being attached or enclosed) and this Certificate of Mailing are being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

By: Richard W. Bork  
Richard W. Bork

Date: August 11, 1997

Mailing Address:

MORGAN & FINNEGAN, L.L.P.  
345 Park Avenue  
New York, New York 10154  
(212) 758-4800  
(212) 751-6849 Telecopier

FORM: CERTMAIL.NY  
Rev. 3/27/95



PATENT  
Docket No. 2026-4255

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Emerson, S.U. et al. Group Art Unit: 1815  
Serial No. : 08/840,316 Examiner: To be Assigned  
Filed : April 11, 1997  
For : RECOMBINANT PROTEINS OF A PAKISTANI STRAIN OF  
HEPATITIS E AND THEIR USE IN DIAGNOSTIC METHODS AND  
VACCINES

TRANSMITTAL OF DECLARATION PURSUANT TO 37 C.F.R. § 1.53(d)

ASSISTANT COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

Sir:

Transmitted herewith is a declaration for the above-identified application.

The surcharge, pursuant to 37 C.F.R. § 1.16(e), for filing a declaration on a date later than the filing date of the application is as follows:

- ☐ Filing by a small entity  
\$65.00
- ☒ Filing by other than a small entity  
\$130.00
- ☐ Charge fee to Deposit Account No. 13-4500. Order No. \_\_\_\_\_  
A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
- ☒ A check in the amount of \$ 130.00 to cover the surcharge is enclosed.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required by this paper, or credit any overpayment to Deposit Account No. 13-4500. Order No. 2026-4255.

PATENT  
Docket No. 2026-4255

A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,

MORGAN & FINNEGAN


Date: August 11, 1997

By: *Richard W. Bork*  
Richard W. Bork  
Registration No. 36,459  
(212) 415-8645 (Direct)

Mailing Address:

MORGAN & FINNEGAN, L.L.P.  
345 Park Avenue  
New York, New York 10154  
(212) 758-4800  
(212) 751-6849 Telecopier

CF  
6/4



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NUMBER 37-970 840,325	FILING/RECEIPT DATE 04/11/97	FIRST-NAMED APPLICANT EMERSON	ATTORNEY DOCKET NO./TITLE S 2026-4255
---	---------------------------------	----------------------------------	--

0292/0609  
OFFICE OF TECHNOLOGY TRANSFER  
PATENT BRANCH  
NATIONAL INSTITUTES OF HEALTH  
6011 EXECUTIVE BOULEVARD SUITE 325  
ROCKVILLE MD 20852  
NOT ASSIGNED  
DATE MAILED: 1815  
06/09/97

**NOTICE TO FILE MISSING PARTS OF APPLICATION**  
**Filing Date Granted**

An Application Number and Filing Date have been assigned to this application: However, the items indicated below are missing. The required items and fees identified below must be timely submitted **ALONG WITH THE PAYMENT OF A SURCHARGE** for items 1 and 3-6 only of \$ 125 for a ☒ large entity ☐ small entity in compliance with 37 CFR 1.27. The surcharge is set forth in 37 CFR 1.16(e). Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file all required items and pay any fees required above to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

If all required items on this form are filed within the period set above, the total amount owed by applicant as a ☒ large entity ☐ small entity (verified statement filed), is \$ 120.

- ☐ 1. The statutory basic filing fee is:
  - ☐ missing.
  - ☐ insufficient.

*Applicant must submit \$ to complete the basic filing fee and/or file a verified small entity statement claiming such status (37 CFR 1.27).*
- ☐ 2. Additional claim fees of \$ \_\_\_\_\_, including any multiple dependent claim fees, are required.  
*Applicant must either submit the additional claim fees or cancel additional claims for which fees are due.*
- ☐ 3. The oath or declaration:
  - ☐ is missing.
  - ☐ does not cover the newly submitted items.
  - ☐ does not identify the application to which it applies.
  - ☐ does not include the city and state or foreign country of applicant's residence.

*An oath or declaration in compliance with 37 CFR 1.63, including residence information and identifying the application by the above Application Number and Filing Date is required.*
- ☒ 4. The signature(s) to the oath or declaration is/are:
  - ☒ missing.
  - ☐ by a person other than inventor or person qualified under 37 CFR 1.42, 1.43, or 1.47.

*A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.*
- ☐ 5. The signature of the following joint inventor(s) is missing from the oath or declaration:  

*An oath or declaration listing the names of all inventors and signed by the omitted inventor(s), identifying this application by the above Application Number and Filing Date, is required.*
- ☐ 6. A \$ \_\_\_\_\_ processing fee is required since your check was returned without payment (37 CFR 1.21(n)).
- ☐ 7. Your filing receipt was mailed in error because your check was returned without payment.
- ☒ 8. The application does not comply with the Sequence Rules.  
*See attached Notice to Comply with Sequence Rules 37 CFR 1.821-1.825.*
- ☐ 9. OTHER:

Direct the response and any questions about this notice to "Attention: Box Missing Parts."

**A copy of this notice MUST be returned with the response.**

*Whitney*  
Customer Service Center  
Initial Patent Examination Division (703) 308-1202

**BEST AVAILABLE COPY**

Application No.: 08/840316

**PLEASE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

If a nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**

**BEST AVAILABLE COPY**